Skip to content

Stephanie Reisinger to Lead Flatiron Health’s Real-World Evidence Business

Published

January 2022

Stephanie Reisinger to Lead Flatiron Health’s Real-World Evidence Business

Former Veradigm Executive Brings Extensive Experience in EHR-Derived Real-World Data 

NEW YORK, NY

Flatiron Health® today announced the appointment of Stephanie Reisinger as Senior Vice President and General Manager, Real-World Evidence (RWE), driving long-term strategy and growth for Flatiron’s RWE business unit.

“Stephanie brings a unique mix of expertise across electronic health records, real-world evidence, and analytics – the pillars of Flatiron’s work to learn from the experiences of every cancer patient,” said Carolyn Starrett, Flatiron CEO. “I’ve been deeply impressed by her perspective, accomplishments, and vision. Her leadership will help take our well-established products and evidence platform to the next level.”

Flatiron has led the field in the creation and use of RWE for oncology research and development (R&D). Today – together with a highly engaged care network of community sites, academic medical centers and health systems along with its life sciences and regulatory partners – Flatiron continues to drive and shape the future of oncology evidence generation.

Flatiron recognizes that to meaningfully accelerate R&D and access, to make research more inclusive and healthcare more sustainable, fundamental changes must be made in the way required data is collected, combined and analyzed. Through integrated evidence, knowledge can be generated in ways that go beyond today’s methods – increasingly incorporating additional data modalities like genomics, claims and imaging; extending the stories told by clinical trial data with real-world data (RWD). Supported by Reisinger’s leadership, Flatiron will accelerate this vision to enable integrated evidence to power smarter care for every patient.

Prior to Flatiron, Reisinger served as the General Manager of Life Sciences Data and Analytics at Veradigm, an analytics subsidiary of Allscripts. She scaled the Life Sciences and RWE businesses, bridging the gap between Allscripts’ payer and provider data and life sciences partners, and oversaw operations and go-to-market strategy for this business unit. She has also held senior leadership positions in a variety of healthcare data and analytics organizations, including Evalytica, Evidera, United BioSource Corporation, ProSanos and GeneFormatics. Reisinger earned her bachelor’s degree at Widener University and is a candidate for her master’s in business administration at the Smeal College of Business at Penn State University.

“I am honored to join Flatiron, a global leader in transforming patients’ real-life experiences into knowledge to help accelerate improvements in cancer care and treatments,” said Reisinger. “I look forward to working closely with the organization’s talented and mission-driven colleagues, as we continue to grow, lead and innovate. Flatiron has been at the forefront of developing real-world data for cancer research and I am delighted at the opportunity to be able to contribute to their mission and lead this next chapter of innovation alongside our partners.”

Location:
NEW YORK, NY, January 5, 2022

About Flatiron Health

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

Media Contact

Nina Toor

press@flatiron.com

Share